Justin Bowers

can you talk about the conversion rates and the velocity of decision-making that you're seeing

speaking with a top 10 pharma last week, and we were talking about AI and how that would potentially impact early stage

I want to sort of follow up on Luke’s earlier question, and hopefully, you can educate us a little bit more on NAMS

Do you have LOIs for any of those assets? And do you plan on treating that as discontinued ops going forward?

Was that consistent across globals or biotechs? Or was it weighted one way or the other?

there's been a decent uptick in licensing deals out of China over the last few quarters. And I was just hoping you could help us think through sort of the pushes and pulls on the business

Is that something that you've seen continue through May, number one? Number two, I wasn't sure if you said that, that was isolated to large pharma

is that delta price or mix or discovery? Just sort of help us peel the onion back a little bit there

Is that more of a function of how customers are deploying their clinical strategy

is it sort of accretive, mutual or decremental to growth, whether it's RTS

Is this a momentum that we should expect to continue over the next few quarters and into 2026

drivers behind the strength in RWE in the quarter, how the order book looks through the balance of the year

can you update us on your view for fourth quarter for the different end markets?

when you double-click on the funding analysis, what sort of competitive dynamics, if any, did you uncover?

Can you point to which cohort of instruments across the portfolio that might be the beneficiary -- biggest beneficiaries of this

are you still looking for sort of like low-single digit in Protein Sciences and then call it mid-teens and DSB?

Can you help us understand how indicative of that is in a recovery in the end market versus ongoing market share gains?

Can you help us understand the appetite for customers to reinvest in early stage and for your upstream in R&D and what you're seeing there?

Was that mostly volume driven? Or was there any incentive payments there?

can you provide us with an update on the demand profile for some of the manufacturing space that you now have available in Dublin

are they speccing in on a different type of HVP component, i.e., like a NovaPure or a FluroTec or just a different configuration

There were some updates earlier this year. And just curious how that's impacting customer decision-making and some of the conversions

generics was particularly strong in the quarter, and I think we're anticipating that to be a little more challenged through the year

with the increase in demand and the timing shift, should we infer that some of that demand spills over into 2026?

on the 100 basis points of growth expansion from Annex One, is that referring to 2025 specifically

Is there any anticipated, you know, restock there or are those, you know, back to run rate levels?